Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTI-010 for GVHD Prophylaxis in Hematologic Malignancies
NCT00081055Phase 2Withdrawn
- Sponsor
- Mesoblast Ltd
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remestemcel-L-rknd in graft-versus-host disease (GVHD) (3 arms), sponsored by Mesoblast Ltd. Primary endpoint: Incidence of acute GVHD grade II-IV of skin, liver and gut at Day 84. Status: withdrawn.
02
Drugs
remestemcel-L-rknd
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00081055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081055.